| Affiliation: | (1) Department of Medicine, Division of Oncology, Stanford University, 875 Blake Wilbur Drive, Stanford, CA 94305-5826, USA;(2) Stanford Cancer Institute, Stanford, CA, USA;(3) Eli Lilly and Company, Indianapolis, IN, USA;(4) Present address: Department of Medicine, Division of Pulmonary and Critical Care Medicine, Virginia Commonwealth University Medical Center, Richmond, VA, USA; |
| Abstract: | Purpose Enzastaurin, an oral serine/threonine kinase inhibitor, targets the protein kinase C and AKT pathways with anti-tumor and anti-angiogenic effects. Erlotinib, an oral epidermal growth factor receptor (EGFR) inhibitor, has activity in solid tumors. Based on the promising combination of EGFR inhibitors and anti-angiogenic agents, this phase I trial was initiated. |
